ID30106A - Pelarutan enzimatik modulator-modulator reseptor estrogen selektif - Google Patents

Pelarutan enzimatik modulator-modulator reseptor estrogen selektif

Info

Publication number
ID30106A
ID30106A IDP00200100361D ID20010361D ID30106A ID 30106 A ID30106 A ID 30106A ID P00200100361 D IDP00200100361 D ID P00200100361D ID 20010361 D ID20010361 D ID 20010361D ID 30106 A ID30106 A ID 30106A
Authority
ID
Indonesia
Prior art keywords
estrogent
enzimatic
selective
solution
receptor modulators
Prior art date
Application number
IDP00200100361D
Other languages
English (en)
Inventor
Kevin Kun-Chin Liu
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID30106A publication Critical patent/ID30106A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
IDP00200100361D 2000-05-08 2001-05-04 Pelarutan enzimatik modulator-modulator reseptor estrogen selektif ID30106A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20241800P 2000-05-08 2000-05-08

Publications (1)

Publication Number Publication Date
ID30106A true ID30106A (id) 2001-11-08

Family

ID=22749787

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP00200100361D ID30106A (id) 2000-05-08 2001-05-04 Pelarutan enzimatik modulator-modulator reseptor estrogen selektif

Country Status (24)

Country Link
US (3) US6828134B2 (id)
EP (1) EP1156120B1 (id)
JP (1) JP2002000293A (id)
KR (1) KR100488385B1 (id)
CN (1) CN1322842A (id)
AR (1) AR031844A1 (id)
AT (1) ATE346159T1 (id)
AU (1) AU782597B2 (id)
BR (1) BR0101802A (id)
CA (1) CA2346426C (id)
CZ (1) CZ20011576A3 (id)
DE (1) DE60124616T2 (id)
ES (1) ES2274854T3 (id)
HK (1) HK1040264A1 (id)
HU (1) HUP0101874A3 (id)
ID (1) ID30106A (id)
IL (2) IL168341A (id)
MX (1) MXPA01004626A (id)
PL (1) PL347407A1 (id)
RU (1) RU2213778C2 (id)
SG (1) SG100688A1 (id)
TW (1) TWI237059B (id)
YU (1) YU31101A (id)
ZA (1) ZA200103666B (id)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CN109750013B (zh) * 2019-03-27 2023-01-13 云南师范大学 一种脂肪酶突变体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814282A (en) * 1984-05-03 1989-03-21 Abbott Laboratories Centrifuge for two-dimensional centrifugation
DE3638762A1 (de) * 1986-11-13 1988-05-26 Schering Ag Racematspaltung von 7(alpha)-acyloxy-6ss-hydroxy-methyl-2-oxabicyclo (3.3.0)octan-3-onen durch stereospezifische enzymatische acylat-hydrolyse
US5248609A (en) * 1986-11-13 1993-09-28 Schering Aktiengesellschaft Racemic separation of 7α-acyloxy-6β-hydroxymethyl-2-oxabicyclo[3.]-octan-3-ones by stereospecific enzymatic acylate hydrolysis
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
US5106750A (en) * 1988-08-30 1992-04-21 G. D. Searle & Co. Enantio- and regioselective synthesis of organic compounds using enol esters as irreversible transacylation reagents
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
FR2724184B1 (fr) * 1994-09-05 1997-01-03 Rhone Poulenc Chimie Procede de resolution d'un melange d'alcools stereoisomeres
US5589482A (en) * 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
AU8058398A (en) * 1997-06-17 1999-01-04 Schering Corporation Enzymatic kinetic resolution of an intermediate useful for preparing substitutedtricyclics
PA8475901A1 (es) 1998-06-16 2000-05-24 Pfizer Prod Inc Terapia de combinacion para la fragilidad musculoesqueletica
ID23459A (id) 1998-08-28 2000-04-27 Pfizer Prod Inc Biotransformasi mikroba
US6180375B1 (en) 1999-08-27 2001-01-30 Pfizer Inc. Microbial biotransformation

Also Published As

Publication number Publication date
CN1322842A (zh) 2001-11-21
CZ20011576A3 (cs) 2002-02-13
CA2346426C (en) 2006-08-01
HUP0101874A3 (en) 2003-06-30
IL168341A (en) 2006-08-01
US20040176415A1 (en) 2004-09-09
EP1156120A2 (en) 2001-11-21
TWI237059B (en) 2005-08-01
CA2346426A1 (en) 2001-11-08
DE60124616D1 (de) 2007-01-04
HUP0101874A2 (hu) 2002-03-28
KR100488385B1 (ko) 2005-05-11
JP2002000293A (ja) 2002-01-08
ZA200103666B (en) 2002-11-07
ATE346159T1 (de) 2006-12-15
PL347407A1 (en) 2001-11-19
US20020049219A1 (en) 2002-04-25
EP1156120A3 (en) 2004-02-18
AU782597B2 (en) 2005-08-11
RU2213778C2 (ru) 2003-10-10
KR20010102942A (ko) 2001-11-17
DE60124616T2 (de) 2007-09-13
HU0101874D0 (en) 2001-07-30
ES2274854T3 (es) 2007-06-01
AU4375801A (en) 2001-11-15
IL142881A0 (en) 2002-03-10
MXPA01004626A (es) 2004-09-10
BR0101802A (pt) 2001-12-18
EP1156120B1 (en) 2006-11-22
YU31101A (sh) 2005-07-19
SG100688A1 (en) 2003-12-26
IL142881A (en) 2006-08-01
HK1040264A1 (zh) 2002-05-31
AR031844A1 (es) 2003-10-08
US20070249025A1 (en) 2007-10-25
US6828134B2 (en) 2004-12-07
US7351567B2 (en) 2008-04-01

Similar Documents

Publication Publication Date Title
NO20015272L (no) Glukokortikoid reseptor modulatorer
ATE293962T1 (de) Adenosin-rezeptor modulatoren
PL374215A1 (en) Selective estrogen receptor modulators
DE60109466D1 (de) Flüssigkristallmischung
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
NO20025142L (no) PPAR-<gamma>-modulatorer
DE50100900D1 (de) Fixierelement
EP1418900A4 (en) SELECTIVE ESTROGEN RECEPTOR MODULATORS
DE10085449T1 (de) Fixiervorrichtung
NO20013997D0 (no) Reseptoranalyse
ES1050639Y (es) Dispositivo de soporte de ducha
DE60121569D1 (de) Verteiltes vorrausbezahlte kommunikationsinfrastruktur
IL154984A0 (en) Estrogen receptor modulators
NO20013860L (no) 16-hydroksyöstratriener som selektive östrogener
DE60210333D1 (de) Tetracyclische heteroverbindungen als modulatoren des östrogenrezeptors
ID30106A (id) Pelarutan enzimatik modulator-modulator reseptor estrogen selektif
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
EP1680101A4 (en) DEVELOPMENT OF NEW SELECTIVE OESTROGEN RECEPTOR MODULATORS
DE60135621D1 (de) Fixiergerät
NO20005773D0 (no) Pyroteknisk struktur
NO20015378L (no) Cyklokarbamatderivater som progesteronreseptormodulatorer
DE60119386D1 (de) Verbessertes transfektionssystem
DE60038283D1 (de) Mischvorrichtung
LT2000015A (lt) Nesteroidiniai ligandai estrogeno receptoriui
DE60102324D1 (de) Mischeinheit